本文選題：新輔助內(nèi)分泌治療 + 前列腺癌��； 參考：《青島大學(xué)》2017年碩士論文

【摘要】：目的:探究新輔助內(nèi)分泌藥物療法對(duì)T3N0M0期前列腺癌根治術(shù)圍手術(shù)期療效的影響。方法:通過回顧性地收集并分析自2010年1月至2016年10月,青島大學(xué)附屬青島市市立醫(yī)院泌尿外科收治的64例T3N0M0期前列腺癌患者的住院病例資料,根據(jù)治療方式的不同分為聯(lián)合治療組(43例)和單純手術(shù)組(21例)。手術(shù)均成功完成。行前列腺癌根治術(shù)治療前兩組患者的基本情況(年齡、體質(zhì)指數(shù)、前列腺體積、PSA水平)的差異無統(tǒng)計(jì)學(xué)意義(PO.05),通過統(tǒng)計(jì)學(xué)軟件對(duì)比分析兩組患者的手術(shù)時(shí)間、術(shù)中失血量、術(shù)后住院時(shí)間、切緣陽性率、術(shù)后Gleason評(píng)分、術(shù)后尿管留置時(shí)間、控尿恢復(fù)時(shí)間、術(shù)后各種手術(shù)相關(guān)并發(fā)癥發(fā)生率等臨床數(shù)據(jù)資料,來探究新輔助內(nèi)分泌治療對(duì)T3N0M0期前列腺癌患者根治術(shù)圍手術(shù)期療效的影響。結(jié)果:兩組患者均成功實(shí)施腹腔鏡前列腺癌根治術(shù),無中轉(zhuǎn)開放。新輔助內(nèi)分泌治療可以明顯使T3N0M0期腫瘤的前列腺體積減小,使血清PSA水平明顯降低。兩組的手術(shù)時(shí)間、術(shù)中失血量、術(shù)后住院時(shí)間、盆腔引流時(shí)間、術(shù)后Gleason評(píng)分、尿管留置時(shí)間、手術(shù)相關(guān)的并發(fā)癥發(fā)生率等差異均無顯著統(tǒng)計(jì)學(xué)意義(P0.05)。聯(lián)合治療組的術(shù)中控尿恢復(fù)時(shí)間低于單純手術(shù)組(P0.05),聯(lián)合治療組的手術(shù)腫瘤切緣陽性率低于單純手術(shù)組的腫瘤切緣陽性率,差異均有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:新輔助內(nèi)分泌治療聯(lián)合前列腺癌根治術(shù)治療T3N0M0期前列腺癌是安全并且可行的。新輔助內(nèi)分泌治療能夠明顯減小T3N0M0期前列腺癌的前列腺體積、顯著降低血清PSA水平。新輔助內(nèi)分泌治療對(duì)于T3N0M0期前列腺癌患者的圍手術(shù)期一般指標(biāo)并沒有顯著影響,并未明顯增加手術(shù)風(fēng)險(xiǎn)。新輔助內(nèi)分泌治療可以降低T3N0M0期前列腺癌的手術(shù)腫瘤切緣陽性率,可以相應(yīng)縮短根治術(shù)后控尿恢復(fù)時(shí)間。
[Abstract]:Objective: to investigate the effect of neoadjuvant endocrine therapy on perioperative efficacy of T3N0M0 radical prostatectomy for prostate cancer. Methods: from January 2010 to October 2016, 64 cases of T3N0M0 stage prostate cancer were collected and analyzed retrospectively from the Department of Urology, Qingdao City Hospital affiliated to Qingdao University. According to the different treatment methods, the patients were divided into combined treatment group (n = 43) and simple operation group (n = 21). The operation was completed successfully. There was no significant difference between the two groups (age, body mass index, prostate volume PSA level) before radical prostatectomy. The time of operation and blood loss during operation were analyzed by statistical software. Clinical data such as postoperative hospitalization time, positive rate of incision margin, postoperative Gleason score, postoperative urinary catheter indwelling time, recovery time of controlled urine, incidence of postoperative complications and other clinical data, etc. To explore the effect of neoadjuvant endocrine therapy on perioperative outcome in patients with T3N0M0 prostate cancer. Results: laparoscopic radical prostatectomy was performed successfully in both groups. Neoadjuvant endocrine therapy can significantly reduce the prostate volume and serum PSA level of T3N0M0 stage tumors. There were no significant differences in operation time, blood loss, postoperative hospitalization time, pelvic drainage time, postoperative Gleason score, urinary catheter indwelling time and the incidence of complications related to operation between the two groups (P 0.05). The recovery time of controlled urine in the combined treatment group was lower than that in the simple operation group (P 0.05), and the positive rate of the surgical resection margin in the combined treatment group was lower than that in the simple operation group (P 0.05). Conclusion: neoadjuvant endocrine therapy combined with radical prostatectomy for T3N0M0 stage prostate cancer is safe and feasible. Neoadjuvant endocrine therapy can significantly reduce prostate volume and serum PSA level of T3N0M0 prostate cancer. Neo-adjuvant endocrine therapy has no significant effect on perioperative parameters of patients with T3N0M0 prostate cancer and does not significantly increase the risk of surgery. Neoadjuvant endocrine therapy can reduce the positive rate of resection margin of prostate cancer in T3N0M0 stage and shorten the recovery time of urinary control after radical operation.
【學(xué)位授予單位】：青島大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.25

【參考文獻(xiàn)】

相關(guān)期刊論文 前3條

1 Wanqing Chen;;Cancer statistics: updated cancer burden in China[J];Chinese Journal of Cancer Research;2015年01期

2 俞琴;冉隆富;莫云海;韓林梅;袁蓉;;1.5T磁共振LAVA動(dòng)態(tài)增強(qiáng)對(duì)前列腺癌及增生的診斷價(jià)值[J];現(xiàn)代臨床醫(yī)學(xué);2015年01期

3 韓蘇軍;張思維;陳萬青;李長(zhǎng)嶺;;中國(guó)前列腺癌發(fā)病現(xiàn)狀和流行趨勢(shì)分析[J];臨床腫瘤學(xué)雜志;2013年04期

，

本文編號(hào)：1810110